Fortis Capital Management LLC Raises Stock Position in Eli Lilly and Company $LLY

Fortis Capital Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 1,849.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,267 shares of the company’s stock after buying an additional 7,843 shares during the period. Fortis Capital Management LLC’s holdings in Eli Lilly and Company were worth $6,308,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in LLY. MainStreet Investment Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $1,446,000. Private Advisory Group LLC increased its position in shares of Eli Lilly and Company by 15.5% during the 3rd quarter. Private Advisory Group LLC now owns 20,682 shares of the company’s stock valued at $15,780,000 after purchasing an additional 2,782 shares during the last quarter. Verus Capital Partners LLC raised its holdings in Eli Lilly and Company by 3.7% during the 3rd quarter. Verus Capital Partners LLC now owns 1,227 shares of the company’s stock valued at $936,000 after buying an additional 44 shares during the period. American Money Management LLC lifted its position in Eli Lilly and Company by 4.3% in the third quarter. American Money Management LLC now owns 4,977 shares of the company’s stock worth $3,797,000 after buying an additional 205 shares during the last quarter. Finally, Arbor Trust Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 2.9% during the third quarter. Arbor Trust Wealth Advisors LLC now owns 2,251 shares of the company’s stock worth $1,718,000 after buying an additional 63 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Landmark long‑term Omvoh (mirikizumab) data — Phase 3 VIVID‑2 open‑label results showed >90% of Crohn’s patients who reached steroid‑free remission at one year remained steroid‑free at three years; low hospitalization and surgery rates reinforce Omvoh’s potential to reduce disease complications and extend market opportunity in IBD. Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh
• Positive Sentiment: Additional trial wins — Lilly reported another positive result for the Zepbound‑Taltz combination (psoriasis/obesity crossover strategy) and other pipeline progress that support revenue diversification beyond GLP‑1s. These clinical wins strengthen near‑ and medium‑term growth expectations. Lilly chalks up another trial win for Zepbound‑Taltz combo
• Positive Sentiment: Analyst support — Berenberg raised its price target from $950 to $1,050 while keeping a hold rating, signaling modest upside in analyst models that may buoy sentiment after recent gains. Berenberg adjusts price target on Eli Lilly
• Neutral Sentiment: Business development — Lilly entered a $100M licensing deal with CSL for clazakizumab, which diversifies partnerships and could add mid‑late‑stage value but is not immediately material to top‑line. Eli Lilly Enters $100 Million Licensing Agreement with CSL Limited
• Neutral Sentiment: New indications / trials — Lilly has launched/updated trials (e.g., brenipatide Phase 2 for opioid use disorder) that expand the pipeline but are early‑stage and carry typical clinical risk/reward. Eli Lilly pushes into opioid use disorder with new brenipatide Phase 2 trial
• Negative Sentiment: Valuation and GLP‑1 concentration risk — Commentary and analysis pieces flag that much of Lilly’s recent rally was driven by GLP‑1/weight‑loss momentum; competition and profitability normalization risks remain, which can prompt profit‑taking and cap further near‑term gains. Warning: This Skyrocketing Stock Has a Hidden Risk

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday. HSBC restated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Finally, CICC Research increased their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,228.54.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,008.47 on Monday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a market cap of $951.35 billion, a price-to-earnings ratio of 43.94, a price-to-earnings-growth ratio of 1.17 and a beta of 0.39. The firm has a 50-day moving average of $1,054.83 and a two-hundred day moving average of $917.84. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.